BioDiem Ltd (BDM) – Strategic SWOT Analysis Review

Date: 2016-01

“BioDiem Ltd (BDM) – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – GlobalData’s summarization of the company’s business strategy.
– SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.


BioDiem Ltd. (BioDiem) is a biotechnology company which focuses on developing and commercializing vaccines and infectious disease therapies. The company develops vaccines and novel therapeutic candidates for the treatment of seasonal and pandemic influenza, antimicrobial and antifungal, and retinal disease. The company’s product portfolio includes Live Attenuated Influenza Virus (LAIV) based influenza vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious human infections. The company partners with other vaccine and infectious disease treatment companies through licensing its LAIV vaccine and other technologies. The LAIV is licensed to World Health Organisation as part of the Global Pandemic Influenza Action Plan. BioDiem is headquartered in Melbourne, Victoria, Australia.

BioDiem Ltd Key Recent Developments

Jul 10, 2015: BioDiem and Griffith University secure grant to continue world class research in anti-microbial drug discovery
Mar 16, 2015: BioDiem Half Year Financial Report
Dec 05, 2013: BioDiem Announces Publication of Research in Journal of Virology
Oct 28, 2013: BioDiem Announces Confirmation of Delisting from ASX
Oct 25, 2013: BioDiem Announces Change of Principal Place of Business and Registered Office

Reasons to Buy

– Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
– Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
– Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
– Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample